Comparative Pharmacology
Head-to-head clinical analysis: ULTRAVIST 240 versus ULTRAVIST PHARMACY BULK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTRAVIST 240 versus ULTRAVIST PHARMACY BULK.
ULTRAVIST 240 vs ULTRAVIST (PHARMACY BULK)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated nonionic contrast agent that attenuates X-rays by increasing the density of iodine atoms, enhancing vascular and tissue contrast during imaging procedures. It does not have intrinsic pharmacological activity.
Iodinated nonionic radiographic contrast agent that attenuates X-rays due to its iodine content, providing vascular and tissue opacification during imaging.
IV injection: 1.0-2.0 mL/kg (240 mg I/mL) for CT; total dose not to exceed 250 mL per procedure.
300 mg iodine/mL, 370 mg iodine/mL: 0.6-1.5 mL/kg IV for CT; 100-300 mL IV for angiography. Repeat doses allowed up to maximum total dose of 500 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10-30 hours, necessitating dose adjustment.
Terminal elimination half-life is approximately 1.5-2 hours in patients with normal renal function. Prolonged in renal impairment (up to 10-30 hours) or severe disease.
Primarily renal excretion via glomerular filtration; approximately >90% of the administered dose is excreted unchanged in the urine within 24 hours. Biliary/fecal excretion is negligible (<2%).
Primarily renal by glomerular filtration; approximately 60-70% eliminated unchanged in urine within 6 hours, with >90% excreted within 24 hours. Less than 1% biliary or fecal.
Category C
Category C
Radiographic Contrast Agent (Iodinated Non-Ionic)
Radiographic Contrast Agent (Iodinated Non-Ionic)